Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016-2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides

Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02418-19. doi: 10.1128/AAC.02418-19. Print 2020 Apr 21.

Abstract

Plazomicin was active against 97.0% of 8,783 Enterobacterales isolates collected in the United States (2016 and 2017), and only 6 isolates carried 16S rRNA methyltransferases conferring resistance to virtually all aminoglycosides. Plazomicin (89.2% to 95.9% susceptible) displayed greater activity than amikacin (72.5% to 78.6%), gentamicin (30.4% to 45.9%), and tobramycin (7.8% to 22.4%) against carbapenem-resistant and extensively drug-resistant isolates. The discrepancies among the susceptibility rates for these agents was greater when applying breakpoints generated using the same stringent contemporary methods applied to determine plazomicin breakpoints.

Keywords: aminoglycosides; plazomicin; susceptibility.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoglycosides / pharmacology*
  • Anti-Bacterial Agents / therapeutic use*
  • Carbapenem-Resistant Enterobacteriaceae / drug effects*
  • Drug Resistance, Bacterial / genetics
  • Enterobacteriaceae / drug effects*
  • Enterobacteriaceae / genetics
  • Enterobacteriaceae Infections / microbiology*
  • Hospitals
  • Humans
  • Microbial Sensitivity Tests
  • RNA, Ribosomal, 16S / genetics
  • Sisomicin / analogs & derivatives*
  • Sisomicin / pharmacology
  • United States

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • RNA, Ribosomal, 16S
  • plazomicin
  • Sisomicin